Amniotic stem cell transplantation therapy for type 1 diabetes: a case report

Area of Science:

• Regenerative Medicine
• Immunology
• Endocrinology

Background:

• Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by pancreatic beta-cell destruction, necessitating lifelong insulin therapy.
• Current T1DM management focuses on glycemic control but does not restore endogenous insulin production.
• Allogeneic stem cell transplantation is being investigated as a potential regenerative therapy for T1DM.

Observation:

• A 26-year-old male with T1DM received an infusion of allogeneic amniotic membrane-derived stem cells (2 × 10^7), expressing CD133 and CD34, into the pancreatic dorsal artery.
• The transplantation procedure was performed via the left femoral artery.
• The patient's exogenous insulin requirements began decreasing within 3 days post-transplantation.

Findings:

• The patient achieved complete insulin independence at 3 months post-transplantation, maintaining this status for 6.2 months.
• Over a 36-month follow-up, blood glucose levels remained controlled, with insulin requirements readjusted to 8 IU/day.
• These results indicate a potential improvement in in vivo islet cell function and glucose responsiveness.

Implications:

• Allogeneic amniotic membrane stem cell transplantation shows promise as a novel therapeutic strategy for T1DM.
• Further research is warranted to elucidate the precise mechanisms of action and long-term efficacy.
• Consideration of alternative explanations, such as a honeymoon period, is essential in interpreting these preliminary findings.